World Investment Advisors Raises Stock Position in CVS Health Corporation $CVS

Key Points

• World Investment Advisors boosted its CVS Health stake by 36.5% in the fourth quarter, bringing its holdings to 73,409 shares valued at about $5.8 million. Institutional ownership remains very high, with hedge funds and other institutions holding roughly 80.66% of the stock.
• Wall Street sentiment has turned more positive, with multiple firms raising price targets and issuing buy ratings. CVS now has a consensus Moderate Buy rating and an average target price of $98.88.
• CVS reported strong quarterly results, beating earnings and revenue estimates, and reaffirmed FY 2026 EPS guidance of 7.30 to 7.50. The company also highlighted a 2.9% annualized dividend yield, though insider selling and a Tennessee PBM-related lawsuit add some risk.

World Investment Advisors raised its stake in CVS Health Corporation (NYSE:CVS - Free Report) by 36.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 73,409 shares of the pharmacy operator's stock after buying an additional 19,623 shares during the period. World Investment Advisors' holdings in CVS Health were worth $5,826,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in CVS. Caitong International Asset Management Co. Ltd increased its holdings in CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator's stock valued at $26,000 after buying an additional 281 shares in the last quarter. Swiss RE Ltd. purchased a new position in shares of CVS Health during the 4th quarter worth approximately $26,000. Sankala Group LLC purchased a new position in shares of CVS Health during the 4th quarter worth approximately $28,000. Mcguire Capital Advisors Inc. purchased a new position in shares of CVS Health during the 4th quarter worth approximately $28,000. Finally, Ares Financial Consulting LLC purchased a new position in shares of CVS Health during the 4th quarter worth approximately $29,000. 80.66% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently weighed in on CVS. JPMorgan Chase & Co. raised their price objective on shares of CVS Health from $101.00 to $111.00 and gave the stock an "overweight" rating in a research note on Tuesday, May 12th. Truist Financial raised their price objective on shares of CVS Health from $98.00 to $102.00 and gave the stock a "buy" rating in a research note on Thursday, May 7th. Weiss Ratings reissued a "hold (c)" rating on shares of CVS Health in a research note on Friday, May 8th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of CVS Health from $88.00 to $92.00 and gave the stock a "buy" rating in a research note on Thursday, May 7th. Finally, TD Cowen raised their price objective on shares of CVS Health from $105.00 to $110.00 and gave the stock a "buy" rating in a research note on Monday, May 11th. Twenty-two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, CVS Health presently has an average rating of "Moderate Buy" and a consensus target price of $98.88.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Barclays raised its price target on CVS Health to $106 from $101 and maintained an overweight rating, signaling improved Wall Street confidence in the stock’s upside. Barclays price target raise
• Positive Sentiment: Aetna said its second-generation Claims Assist Manager, an AI-powered claims platform, has cut claims processing time by more than 20% while improving payment accuracy, a potential margin and efficiency tailwind for CVS Health. Aetna AI claims update
• Positive Sentiment: MinuteClinic and Hartford HealthCare expanded primary care access across Connecticut, adding another growth-oriented partnership that could help CVS broaden patient access and utilization. MinuteClinic Hartford HealthCare expansion
• Positive Sentiment: Aetna Better Health of Missouri announced a $175,000 community investment to address food insecurity and safety/wellness supports, reinforcing CVS Health’s Medicaid/community-health positioning. Aetna Missouri community investment
• Neutral Sentiment: CVS Health is also drawing attention for broader analyst commentary, but the article provided did not include a clear new catalyst beyond market discussion. Analyst commentary on CVS Health
• Negative Sentiment: CVS sued Tennessee over a new PBM-pharmacy ownership law, arguing it unlawfully targets out-of-state companies and could force the company to shut pharmacies in the state, creating regulatory and earnings risk. CVS Tennessee lawsuit

Insiders Place Their Bets

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the transaction, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. This trade represents a 87.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Larry Robbins sold 1,983,538 shares of CVS Health stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the completion of the transaction, the director owned 6,213,261 shares in the company, valued at approximately $586,842,501.45. This trade represents a 24.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 3,441,551 shares of company stock worth $323,703,977. 0.85% of the stock is owned by company insiders.

CVS Health Stock Up 1.4%

Shares of NYSE CVS opened at $92.02 on Thursday. CVS Health Corporation has a 1 year low of $58.50 and a 1 year high of $98.43. The firm's 50 day moving average price is $81.35 and its 200 day moving average price is $79.37. The firm has a market cap of $117.41 billion, a P/E ratio of 40.54, a price-to-earnings-growth ratio of 0.89 and a beta of 0.60. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87.

CVS Health (NYSE:CVS - Get Free Report) last announced its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. During the same quarter last year, the business earned $2.25 earnings per share. CVS Health's revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, sell-side analysts anticipate that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were given a dividend of $0.665 per share. The ex-dividend date was Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.9%. CVS Health's dividend payout ratio (DPR) is 117.18%.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.